All FDA-approved EMA-approved PMDA-approved
Target Card Uniprot Example: P23975

ceftazidime 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
antibiotics, cefalosporanic acid derivatives	559	72558-82-8

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: ceftazidime hydrate ceftazidime biotum cefazid ceftacidin ceftazidine tazicef tazidime ceftazidime sodium ceftazidime pentahydrate	Semisynthetic, broad-spectrum antibacterial derived from CEPHALORIDINE and used especially for Pseudomonas and other gram-negative infections in debilitated patients. Molecular weight: 547.58 Formula: C22H23N6O7S2 CLOGP: -3.47 LIPINSKI: 2 HAC: 13 HDO: 4 TPSA: 188.39 ALOGS: -5.11 ROTB: 9 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Drug dosage:

Dose	Unit	Route
4	g	P
6	g	P

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	4	Bocci G, Oprea TI, Benet LZ
S (Water solubility)	0.01 mg/mL	Bocci G, Oprea TI, Benet LZ
EoM (Fraction excreted unchanged in urine)	85 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	156.82 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	0 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution)	0.31 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	2.40 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.79 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	1.80 hours	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company	Orphan
July 19, 1985	FDA	COVIS INJECTABLES

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Aplastic anaemia	182.59	19.93	63	8621	9506	63470832
Drug resistance	83.48	19.93	47	8637	22886	63457452
Toxic epidermal necrolysis	81.75	19.93	48	8636	25286	63455052
Endophthalmitis	81.71	19.93	27	8657	3565	63476773
Acute kidney injury	81.26	19.93	136	8548	263279	63217059
Pathogen resistance	76.96	19.93	30	8654	6368	63473970
Pseudomonas infection	72.95	19.93	34	8650	11179	63469159
Multiple organ dysfunction syndrome	70.62	19.93	60	8624	56692	63423646
Neutropenia	60.18	19.93	95	8589	174910	63305428
Drug reaction with eosinophilia and systemic symptoms	55.34	19.93	42	8642	33794	63446544
Sepsis	55.25	19.93	85	8599	153038	63327300
Infective pulmonary exacerbation of cystic fibrosis	55.08	19.93	26	8658	8791	63471547
Septic shock	53.10	19.93	55	8629	66574	63413764
Fatigue	52.89	19.93	28	8656	888000	62592338
Febrile neutropenia	51.77	19.93	72	8612	118377	63361961
Hyperbilirubinaemia	48.94	19.93	26	8658	11288	63469050
Pancytopenia	48.59	19.93	63	8621	96870	63383468
Adenoviral hepatitis	47.37	19.93	11	8673	390	63479948
Systemic inflammatory response syndrome	45.96	19.93	20	8664	5601	63474737
Cytomegalovirus infection	45.73	19.93	31	8653	20921	63459417
Vanishing bile duct syndrome	45.54	19.93	12	8672	720	63479618
Staphylococcal sepsis	44.81	19.93	22	8662	8106	63472232
Patent ductus arteriosus	44.39	19.93	18	8666	4232	63476106
Endometrial disorder	40.70	19.93	11	8673	728	63479610
Cholestasis	40.50	19.93	33	8651	29401	63450937
Rash maculo-papular	40.22	19.93	34	8650	31862	63448476
Pyrexia	40.02	19.93	148	8536	470330	63010008
Enterococcus test positive	39.95	19.93	12	8672	1161	63479177
Intensive care unit acquired weakness	39.55	19.93	11	8673	810	63479528
Suspected transmission of an infectious agent via product	39.50	19.93	9	8675	293	63480045
Neurotoxicity	39.14	19.93	26	8658	16964	63463374
Peritonitis	38.92	19.93	26	8658	17128	63463210
Disseminated intravascular coagulation	36.45	19.93	26	8658	19025	63461313
Pain	36.33	19.93	29	8655	740599	62739739
Pseudomonal bacteraemia	36.07	19.93	12	8672	1616	63478722
Mucosal inflammation	36.05	19.93	38	8646	46890	63433448
Hepatic failure	35.02	19.93	33	8651	35623	63444715
Venous haemorrhage	34.31	19.93	8	8676	289	63480049
Peripheral sensorimotor neuropathy	32.99	19.93	11	8673	1492	63478846
Abdominal discomfort	32.94	19.93	3	8681	320882	63159456
Encephalopathy	32.79	19.93	33	8651	38587	63441751
Bronchopulmonary aspergillosis	32.23	19.93	18	8666	8617	63471721
Hypopyon	31.59	19.93	9	8675	723	63479615
Fungaemia	31.51	19.93	12	8672	2391	63477947
Myelosuppression	31.40	19.93	26	8658	23677	63456661
Graft versus host disease in gastrointestinal tract	31.37	19.93	13	8671	3228	63477110
Arthralgia	30.92	19.93	20	8664	569690	62910648
Micturition disorder	30.87	19.93	12	8672	2526	63477812
Fungal sepsis	30.71	19.93	10	8674	1260	63479078
Aspergillus infection	30.56	19.93	17	8667	8076	63472262
Acute generalised exanthematous pustulosis	30.55	19.93	19	8665	11080	63469258
Clonus	29.97	19.93	14	8670	4622	63475716
Pulmonary haemorrhage	29.64	19.93	16	8668	7165	63473173
Bacteraemia	29.39	19.93	22	8662	17326	63463012
Respiratory failure	29.19	19.93	51	8633	101807	63378531
Blood bilirubin increased	28.39	19.93	30	8654	37110	63443228
Hepatocellular injury	28.15	19.93	26	8658	27355	63452983
Alopecia	28.02	19.93	6	8678	337530	63142808
Graft versus host disease in liver	28.01	19.93	8	8676	649	63479689
Thrombocytopenia	27.97	19.93	63	8621	151094	63329244
Aplasia	27.96	19.93	13	8671	4246	63476092
Respiratory gas exchange disorder	27.05	19.93	7	8677	391	63479947
Product contamination	26.85	19.93	8	8676	752	63479586
Febrile bone marrow aplasia	26.61	19.93	15	8669	7310	63473028
Eosinophilic pneumonia acute	26.58	19.93	7	8677	419	63479919
Moraxella infection	26.25	19.93	7	8677	440	63479898
Myelopathy	26.23	19.93	11	8673	2815	63477523
Ascites	26.12	19.93	30	8654	40698	63439640
Congestive hepatopathy	25.80	19.93	11	8673	2931	63477407
Linear IgA disease	25.53	19.93	9	8675	1442	63478896
Renal failure	25.16	19.93	52	8632	117600	63362738
Status epilepticus	25.10	19.93	19	8665	15214	63465124
Fibrosis	25.07	19.93	12	8672	4180	63476158
Graft versus host disease	24.97	19.93	14	8670	6749	63473589
Tubulointerstitial nephritis	24.65	19.93	21	8663	19882	63460456
Hepatosplenic candidiasis	24.56	19.93	6	8678	265	63480073
Hepatomegaly	24.54	19.93	17	8667	11872	63468466
Sweat test abnormal	24.43	19.93	4	8680	20	63480318
Generalised bullous fixed drug eruption	24.00	19.93	5	8679	106	63480232
Premature baby	23.90	19.93	21	8663	20714	63459624
Haemophagocytic lymphohistiocytosis	23.84	19.93	16	8668	10611	63469727
Abscess	23.58	19.93	19	8665	16649	63463689
Transfusion	22.93	19.93	18	8666	15199	63465139
Drug intolerance	22.71	19.93	7	8677	308654	63171684
Cardiomyopathy	22.69	19.93	19	8665	17565	63462773
Graft versus host disease in skin	22.66	19.93	10	8674	2895	63477443
Stenotrophomonas infection	22.60	19.93	9	8675	2018	63478320
Stevens-Johnson syndrome	22.43	19.93	22	8662	24928	63455410
Fall	22.33	19.93	13	8671	392321	63088017
Generalised oedema	22.31	19.93	18	8666	15800	63464538
Cardiac arrest	22.30	19.93	43	8641	92502	63387836
Renal tubular necrosis	22.23	19.93	16	8668	11862	63468476
Product dose omission issue	21.99	19.93	3	8681	234310	63246028
Distal intestinal obstruction syndrome	21.98	19.93	6	8678	412	63479926
Poor quality product administered	21.86	19.93	10	8674	3146	63477192
Hepatic necrosis	21.62	19.93	12	8672	5675	63474663
Lower respiratory tract infection bacterial	21.21	19.93	6	8678	470	63479868
Cardiac tamponade	20.72	19.93	11	8673	4764	63475574
Seizure like phenomena	20.17	19.93	7	8677	1072	63479266
Retinal infarction	20.15	19.93	4	8680	66	63480272

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Choroiditis	227.75	19.91	57	11145	1158	34944571
Pathogen resistance	188.24	19.91	81	11121	9401	34936328
Aplastic anaemia	166.98	19.91	75	11127	9641	34936088
Intraocular pressure increased	137.27	19.91	55	11147	5328	34940401
Eye pain	135.19	19.91	72	11130	13390	34932339
Septic shock	129.17	19.91	136	11066	71698	34874031
Uveitis	116.34	19.91	54	11148	7481	34938248
Multiple organ dysfunction syndrome	110.13	19.91	129	11073	76437	34869292
Drug resistance	98.52	19.91	75	11127	25852	34919877
Visual acuity reduced	97.28	19.91	62	11140	16087	34929642
Hyperbilirubinaemia	90.04	19.91	60	11142	16783	34928946
Toxic epidermal necrolysis	87.53	19.91	65	11137	21581	34924148
Drug ineffective	74.09	19.91	315	10887	456436	34489293
Respiratory failure	73.92	19.91	128	11074	108444	34837285
Eosinophilia	72.45	19.91	63	11139	26159	34919570
Pseudomonas infection	68.32	19.91	45	11157	12337	34933392
Drug reaction with eosinophilia and systemic symptoms	63.72	19.91	65	11137	32947	34912782
Fungal peritonitis	54.93	19.91	17	11185	766	34944963
Condition aggravated	51.91	19.91	157	11045	192039	34753690
Mucosal inflammation	50.39	19.91	62	11140	38560	34907169
Fatigue	49.25	19.91	29	11173	370624	34575105
Febrile neutropenia	45.93	19.91	121	11081	136728	34809001
Toxic skin eruption	45.58	19.91	34	11168	11351	34934378
Klebsiella infection	44.63	19.91	30	11172	8501	34937228
Pyrexia	41.44	19.91	213	10989	332800	34612929
Aspergillus infection	41.21	19.91	33	11169	12221	34933508
Fungal sepsis	41.21	19.91	14	11188	850	34944879
Fall	40.40	19.91	8	11194	202877	34742852
Bronchopulmonary aspergillosis	36.07	19.91	33	11169	14626	34931103
Vascular pseudoaneurysm thrombosis	34.91	19.91	7	11195	48	34945681
Acute kidney injury	33.76	19.91	189	11013	304799	34640930
Endophthalmitis	33.06	19.91	18	11184	3490	34942239
Death	32.93	19.91	48	11154	398001	34547728
Candida infection	32.57	19.91	34	11168	17681	34928048
Shock	31.82	19.91	39	11163	24140	34921589
Dizziness	30.54	19.91	16	11186	218505	34727224
Suspected transmission of an infectious agent via product	29.99	19.91	11	11191	837	34944892
Respiratory distress	29.54	19.91	46	11156	35619	34910110
Fungaemia	29.38	19.91	15	11187	2553	34943176
Acute generalised exanthematous pustulosis	28.84	19.91	21	11181	6755	34938974
Clostridium difficile colitis	28.58	19.91	30	11172	15700	34930029
Guillain-Barre syndrome	28.52	19.91	20	11182	6067	34939662
Product contamination	27.90	19.91	10	11192	712	34945017
Cardiac valve vegetation	27.58	19.91	9	11193	482	34945247
Bone marrow failure	27.45	19.91	40	11162	29213	34916516
Febrile bone marrow aplasia	27.37	19.91	22	11180	8187	34937542
Cholestasis	25.51	19.91	37	11165	26911	34918818
Rash maculo-papular	25.40	19.91	38	11164	28413	34917316
Acute respiratory distress syndrome	25.08	19.91	36	11166	25933	34919796
Drug ineffective for unapproved indication	24.57	19.91	34	11168	23681	34922048
Graft versus host disease	24.46	19.91	23	11179	10546	34935183
Clostridium difficile infection	24.09	19.91	30	11172	18868	34926861
Candida pneumonia	24.02	19.91	8	11194	457	34945272
Folliculitis	23.74	19.91	16	11186	4550	34941179
Aplasia	23.67	19.91	16	11186	4572	34941157
Stomatitis	23.65	19.91	46	11156	42468	34903261
Arterial angioplasty	23.26	19.91	5	11197	50	34945679
Herpes zoster reactivation	23.05	19.91	7	11195	296	34945433
Cystic fibrosis	22.87	19.91	11	11191	1647	34944082
Pseudomembranous colitis	22.70	19.91	13	11189	2778	34942951
Cytokine release syndrome	22.51	19.91	32	11170	22845	34922884
Leukopenia	22.50	19.91	57	11145	62799	34882930
Pseudomonal sepsis	22.30	19.91	14	11188	3533	34942196
Chondritis	22.27	19.91	6	11196	164	34945565
Device related sepsis	21.46	19.91	13	11189	3080	34942649
Depression	21.13	19.91	3	11199	97095	34848634
Flavobacterium infection	21.03	19.91	5	11197	81	34945648
Listeriosis	21.02	19.91	9	11193	1029	34944700
Pneumonia pseudomonal	21.01	19.91	14	11188	3908	34941821
Pain	20.76	19.91	21	11181	204654	34741075
Trichosporon infection	20.45	19.91	8	11194	726	34945003
Hepatocellular injury	20.30	19.91	30	11172	22181	34923548
Embolia cutis medicamentosa	20.25	19.91	6	11196	233	34945496

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Aplastic anaemia	350.01	17.01	138	18373	17767	79708110
Pathogen resistance	247.24	17.01	101	18410	14241	79711636
Choroiditis	243.90	17.01	58	18453	1323	79724554
Septic shock	171.66	17.01	175	18336	122626	79603251
Drug resistance	168.50	17.01	111	18400	42102	79683775
Multiple organ dysfunction syndrome	161.99	17.01	168	18343	120078	79605799
Toxic epidermal necrolysis	158.25	17.01	109	18402	44472	79681405
Pseudomonas infection	124.48	17.01	71	18440	20832	79705045
Intraocular pressure increased	119.39	17.01	53	18458	9152	79716725
Drug reaction with eosinophilia and systemic symptoms	117.03	17.01	106	18405	64138	79661739
Fatigue	104.26	17.01	43	18468	929684	78796193
Eye pain	103.93	17.01	79	18432	37499	79688378
Acute kidney injury	102.39	17.01	308	18203	519096	79206781
Hyperbilirubinaemia	101.54	17.01	66	18445	24452	79701425
Endophthalmitis	99.71	17.01	42	18469	6386	79719491
Visual acuity reduced	95.11	17.01	68	18443	29401	79696476
Respiratory failure	95.05	17.01	159	18352	180752	79545125
Uveitis	94.43	17.01	55	18456	16775	79709102
Eosinophilia	84.89	17.01	76	18435	45269	79680608
Drug ineffective	81.75	17.01	477	18034	1080436	78645441
Mucosal inflammation	78.14	17.01	92	18419	75488	79650389
Febrile neutropenia	75.55	17.01	166	18345	230833	79495044
Pyrexia	71.60	17.01	329	18182	678380	79047497
Suspected transmission of an infectious agent via product	66.00	17.01	20	18491	1166	79724711
Bronchopulmonary aspergillosis	64.14	17.01	48	18463	22246	79703631
Aspergillus infection	63.63	17.01	45	18466	19116	79706761
Fungal peritonitis	63.15	17.01	19	18492	1081	79724796
Fall	62.34	17.01	18	18493	487611	79238266
Klebsiella infection	61.87	17.01	41	18470	15679	79710198
Pain	60.73	17.01	45	18466	703757	79022120
Cholestasis	59.87	17.01	67	18444	52042	79673835
Toxic skin eruption	59.72	17.01	46	18465	22247	79703630
Neutropenia	59.71	17.01	174	18337	287536	79438341
Rash maculo-papular	59.18	17.01	69	18442	56009	79669868
Infective pulmonary exacerbation of cystic fibrosis	59.18	17.01	37	18474	12814	79713063
Sepsis	58.87	17.01	166	18345	269262	79456615
Fungaemia	58.14	17.01	26	18485	4565	79721312
Product contamination	56.46	17.01	18	18493	1242	79724635
Acute generalised exanthematous pustulosis	56.09	17.01	40	18471	17214	79708663
Aplasia	53.20	17.01	29	18482	7791	79718086
Fungal sepsis	49.87	17.01	18	18493	1812	79724065
Dizziness	48.91	17.01	31	18480	526410	79199467
Status epilepticus	44.94	17.01	41	18470	25000	79700877
Graft versus host disease	44.67	17.01	33	18478	14993	79710884
Disseminated intravascular coagulation	44.49	17.01	48	18463	35794	79690083
Poor quality product administered	44.11	17.01	20	18491	3625	79722252
Pancytopenia	43.12	17.01	109	18402	165636	79560241
Candida infection	41.96	17.01	48	18463	38166	79687711
Drug intolerance	41.45	17.01	6	18505	264113	79461764
Encephalopathy	40.46	17.01	63	18448	67334	79658543
Arthralgia	40.36	17.01	44	18467	571759	79154118
Peripheral swelling	40.34	17.01	7	18504	269610	79456267
Clostridium difficile colitis	39.65	17.01	43	18468	32240	79693637
Hepatocellular injury	38.10	17.01	51	18460	47542	79678335
Intensive care unit acquired weakness	38.10	17.01	15	18496	1918	79723959
Hypopyon	37.87	17.01	13	18498	1129	79724748
Cytomegalovirus infection	37.72	17.01	48	18463	42596	79683281
Febrile bone marrow aplasia	37.37	17.01	28	18483	12992	79712885
Pain in extremity	37.36	17.01	19	18492	364519	79361358
Endometrial disorder	36.90	17.01	11	18500	606	79725271
Thrombocytopenia	36.74	17.01	140	18371	265119	79460758
Drug ineffective for unapproved indication	36.65	17.01	52	18459	51186	79674691
Abdominal discomfort	36.45	17.01	7	18504	250720	79475157
Vascular pseudoaneurysm thrombosis	36.44	17.01	7	18504	54	79725823
Leukopenia	36.08	17.01	82	18429	116431	79609446
Haemophagocytic lymphohistiocytosis	35.80	17.01	34	18477	21803	79704074
Shock	35.37	17.01	47	18464	43501	79682376
Pseudomonal bacteraemia	34.44	17.01	16	18495	3066	79722811
Device related sepsis	33.96	17.01	20	18491	6220	79719657
Cystic fibrosis	33.85	17.01	17	18494	3863	79722014
Venoocclusive liver disease	33.09	17.01	25	18486	11746	79714131
Stevens-Johnson syndrome	32.94	17.01	43	18468	39123	79686754
Neurotoxicity	32.62	17.01	39	18472	32479	79693398
Cardiac valve vegetation	32.59	17.01	11	18500	908	79724969
Alopecia	32.50	17.01	7	18504	231348	79494529
Adenoviral hepatitis	32.49	17.01	11	18500	916	79724961
Renal tubular necrosis	31.89	17.01	34	18477	25005	79700872
Headache	31.85	17.01	65	18446	653707	79072170
Staphylococcal infection	31.57	17.01	52	18459	58243	79667634
Pseudomonal sepsis	31.55	17.01	19	18492	6155	79719722
Respiratory distress	31.55	17.01	52	18459	58287	79667590
Systemic inflammatory response syndrome	31.46	17.01	24	18487	11441	79714436
Joint swelling	31.16	17.01	14	18497	288632	79437245
Anxiety	30.22	17.01	10	18501	248502	79477375
Staphylococcal sepsis	30.19	17.01	26	18485	14700	79711177
Enterococcus test positive	30.15	17.01	13	18498	2091	79723786
Muscle spasms	29.79	17.01	3	18508	174727	79551150
Guillain-Barre syndrome	29.64	17.01	21	18490	8944	79716933
Venous haemorrhage	28.71	17.01	8	18503	346	79725531
Product preparation error	27.48	17.01	17	18494	5776	79720101
Therapeutic product effect decreased	27.45	17.01	3	18508	163860	79562017
Pneumonia pseudomonal	27.17	17.01	17	18494	5894	79719983
Noninfectious peritonitis	26.42	17.01	7	18504	250	79725627
Acute respiratory distress syndrome	26.18	17.01	41	18470	44026	79681851
Contraindicated product administered	26.10	17.01	3	18508	157535	79568342
Pseudomembranous colitis	26.08	17.01	16	18495	5358	79720519
Mucormycosis	26.08	17.01	19	18492	8450	79717427
Swelling	25.86	17.01	9	18502	216702	79509175
Peripheral sensorimotor neuropathy	25.71	17.01	13	18498	2997	79722880
Off label use	25.66	17.01	322	18189	906893	78818984
Hypogonadism	25.64	17.01	11	18500	1749	79724128
Vanishing bile duct syndrome	25.53	17.01	11	18500	1767	79724110
Transfusion	25.48	17.01	28	18483	21302	79704575
Sinusitis	25.34	17.01	7	18504	195494	79530383
Retinal vasculitis	24.92	17.01	10	18501	1343	79724534
Arterial angioplasty	24.87	17.01	5	18506	50	79725827
Micturition disorder	24.83	17.01	14	18497	4014	79721863
Hepatosplenic candidiasis	24.71	17.01	8	18503	580	79725297
Myelosuppression	24.64	17.01	38	18473	40258	79685619
Scleromalacia	24.35	17.01	5	18506	56	79725821
Renal failure	23.75	17.01	101	18410	200867	79525010
Nasopharyngitis	23.46	17.01	15	18496	253866	79472011
Blood bilirubin increased	23.20	17.01	49	18462	66183	79659694
Musculoskeletal stiffness	23.18	17.01	6	18505	175002	79550875
Generalised oedema	23.07	17.01	28	18483	23681	79702196
Hepatic necrosis	22.69	17.01	18	18493	9082	79716795
Hepatic function abnormal	22.12	17.01	51	18460	73056	79652821
Contusion	21.94	17.01	4	18507	148772	79577105
Malaise	21.93	17.01	51	18460	489818	79236059
Flavobacterium infection	21.74	17.01	5	18506	98	79725779
Bone marrow failure	21.73	17.01	41	18470	51066	79674811
Paraesthesia	21.60	17.01	7	18504	176316	79549561
Bacteraemia	21.56	17.01	32	18479	32792	79693085
Myocardial infarction	21.37	17.01	8	18503	184121	79541756
Graft versus host disease in gastrointestinal tract	21.27	17.01	15	18496	6341	79719536
Cerebrovascular accident	21.20	17.01	5	18506	155287	79570590
Insomnia	20.65	17.01	16	18495	245154	79480723
Gastroenteritis staphylococcal	20.65	17.01	6	18505	302	79725575
Trichosporon infection	20.49	17.01	8	18503	1000	79724877
Stenotrophomonas infection	20.29	17.01	12	18499	3761	79722116
Synovitis	20.29	17.01	5	18506	150729	79575148
Moraxella infection	20.15	17.01	7	18504	630	79725247
Feeling abnormal	20.07	17.01	6	18505	159193	79566684
Sweat test abnormal	19.98	17.01	4	18507	39	79725838
Hepatic failure	19.97	17.01	44	18467	61168	79664709
Ascites	19.95	17.01	50	18461	75512	79650365
Back pain	19.71	17.01	25	18486	304155	79421722
Condition aggravated	19.69	17.01	190	18321	500934	79224943
Myoclonus	19.67	17.01	28	18483	27632	79698245
Linear IgA disease	19.61	17.01	11	18500	3121	79722756
Liver abscess	19.59	17.01	14	18497	6040	79719837
Chondritis	19.40	17.01	5	18506	160	79725717
Peritonitis	19.38	17.01	28	18483	28008	79697869
Keratitis bacterial	19.37	17.01	5	18506	161	79725716
Product use in unapproved indication	19.02	17.01	111	18400	250248	79475629
Fibrosis	18.86	17.01	13	18498	5296	79720581
Pseudomonas test positive	18.81	17.01	9	18502	1843	79724034
Mobility decreased	18.64	17.01	3	18508	122172	79603705
Generalised bullous fixed drug eruption	18.57	17.01	5	18506	190	79725687
Clonus	18.07	17.01	14	18497	6826	79719051
Hypoaesthesia	17.40	17.01	10	18501	179342	79546535
Graft versus host disease in skin	17.29	17.01	13	18498	6060	79719817
Nausea	17.25	17.01	141	18370	957055	78768822
Geotrichum infection	17.21	17.01	7	18504	974	79724903
Listeriosis	17.15	17.01	9	18502	2241	79723636

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	J01DD02	ANTIINFECTIVES FOR SYSTEMIC USE ANTIBACTERIALS FOR SYSTEMIC USE OTHER BETA-LACTAM ANTIBACTERIALS Third-generation cephalosporins
ATC	J01DD52	ANTIINFECTIVES FOR SYSTEMIC USE ANTIBACTERIALS FOR SYSTEMIC USE OTHER BETA-LACTAM ANTIBACTERIALS Third-generation cephalosporins
CHEBI has role	CHEBI:36047	antibacterial drugs
CHEBI has role	CHEBI:50696	PBP3 inhibitor
CHEBI has role	CHEBI:88188	allergenic drug
MeSH PA	D000900	Anti-Bacterial Agents
MeSH PA	D000890	Anti-Infective Agents

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Gonococcal meningitis	indication	151004
Septicemia due to Escherichia coli	indication	9323009
Bacterial septicemia	indication	10001005	DOID:0040085
Ecthyma gangrenosum	indication	17732003
Infection of skin AND/OR subcutaneous tissue	indication	19824006
Staphylococcal pneumonia	indication	22754005
Streptococcal septicemia	indication	29577008
Pneumonia due to Streptococcus	indication	34020007
Pneumonia due to Pseudomonas	indication	41381004
Peritonitis	indication	48661000
Lower respiratory tract infection	indication	50417007
Pneumonia due to Escherichia coli	indication	51530003
Bacterial pneumonia	indication	53084003	DOID:874
Klebsiella cystitis	indication	60867007
Haemophilus influenzae pneumonia	indication	70036007
Infection due to Escherichia coli	indication	71057007
Rhinoscleroma	indication	72409005	DOID:11336
Endometritis	indication	78623009	DOID:1002
Septicemia due to Serratia	indication	82091000
Bacterial meningitis	indication	95883001	DOID:9470
Infection of bone	indication	111253001
Infectious disease of abdomen	indication	128070006
Infection due to Enterobacteriaceae	indication	128945009
Bacterial infection due to Klebsiella pneumoniae	indication	186435004
Meningococcal meningitis	indication	192644005
Proteus pneumonia	indication	195888009
Neonatal meningitis	indication	276674008
Escherichia coli urinary tract infection	indication	301011002
Proteus urinary tract infection	indication	301012009
Streptococcus pyogenes infection	indication	302809008
Bacterial urinary infection	indication	312124009
Infectious disorder of joint	indication	363162000
Infection due to Staphylococcus aureus	indication	406602003
Osteomyelitis due to Staphylococcus aureus	indication	428783003
Sepsis due to Staphylococcus aureus	indication	448417001
Sepsis due to Pseudomonas	indication	448813005
Urinary tract infection caused by Klebsiella	indication	369001000119100
H. Influenzae Meningitis	indication
Enterobacter Osteomyelitis	indication
E. Coli Cervicitis	indication
Pseudomonas Aeruginosa Joint Infection	indication
Pseudomonas Aeruginosa Osteomyelitis	indication
E. Coli Pelvic Inflammatory Disease	indication
Pseudomonas Aeruginosa Urinary Tract Infection	indication
Complicated Proteus UTI	indication
E. Coli Gynecological Infections	indication
Skin and Skin Structure Proteus Infection	indication
E. Coli Endometritis	indication
Haemophilus Septicemia	indication
Klebsiella Pneumoniae Peritonitis	indication
Inflammatory Disease of Female Pelvic Organs	indication
Skin and Skin Structure Serratia Infection	indication
Enterobacter Pneumonia	indication
E. Coli Pelvic Cellulitis	indication
EnterobacterJoint Infection	indication
Staphylococcus Aureus Joint Infection	indication
Staphylococcus Peritonitis	indication
Klebsiella Pneumoniae Osteomyelitis	indication
Skin and Skin Structure Pseudomonas Aeruginosa Infection	indication
Klebsiella Joint Infection	indication
E. Coli Peritonitis	indication
Complicated UTI with Pseudomonas Aeruginosa	indication
Citrobacter Pneumonia	indication
Pyrexia of unknown origin	off-label use	7520000
Pseudotuberculosis	off-label use	36753006
Infection by Yersinia enterocolitica	off-label use	80960004
Melioidosis	off-label use	428111003	DOID:5052
Ventilator-acquired pneumonia	off-label use	429271009
Pseudomonas Respiratory Tract Infection in Cystic Fibrosis	off-label use
Diabetic Foot Infection	off-label use
Blood coagulation disorder	contraindication	64779008	DOID:1247
Factor II deficiency	contraindication	73975000
Kidney disease	contraindication	90708001	DOID:557
Disease of liver	contraindication	235856003	DOID:409
Pseudomembranous enterocolitis	contraindication	397683000

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	2.53	acidic
pKa2	3.47	acidic
pKa3	13.61	acidic
pKa4	3.1	Basic

Orange Book patent data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Patent number	Patent expiration date	Patent use
EQ 0.5GM BASE;2GM/VIAL	AVYCAZ	ALLERGAN	N206494	Feb. 25, 2015	RX	POWDER	INTRAVENOUS	7112592	Jan. 7, 2026	A METHOD OF TREATING BACTERIAL INFECTIONS IN COMPLICATED INTRA-ABDOMINAL INFECTION AND COMPLICATED URINARY TRACT INFECTION, INCLUDING PYELONEPHRITIS, PATIENTS COMPRISING ADMINISTERING A BACTERICIDALLY EFFECTIVE AMOUNT OF AVIBACTAM SODIUM
EQ 0.5GM BASE;2GM/VIAL	AVYCAZ	ALLERGAN	N206494	Feb. 25, 2015	RX	POWDER	INTRAVENOUS	7112592	Jan. 7, 2026	A METHOD OF TREATING BACTERIAL INFECTIONS IN HOSPITAL-ACQUIRED BACTERIAL PNEUMONIA AND VENTILATOR-ASSOCIATED BACTERIAL PNEUMONIA (HABP/VABP) PATIENTS COMPRISING ADMINISTERING A BACTERICIDALLY EFFECTIVE AMOUNT OF AVIBACTAM SODIUM
EQ 0.5GM BASE;2GM/VIAL	AVYCAZ	ALLERGAN	N206494	Feb. 25, 2015	RX	POWDER	INTRAVENOUS	7112592	Jan. 7, 2026	METHOD OF TREATING BACTERIAL INFECTIONS

Orange Book exclusivity data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Exclusivity date	Description
EQ 0.5GM BASE;2GM/VIAL	AVYCAZ	ALLERGAN	N206494	Feb. 25, 2015	RX	POWDER	INTRAVENOUS	Feb. 25, 2020	NEW CHEMICAL ENTITY
EQ 0.5GM BASE;2GM/VIAL	AVYCAZ	ALLERGAN	N206494	Feb. 25, 2015	RX	POWDER	INTRAVENOUS	Feb. 25, 2025	GENERATING ANTIBIOTIC INCENTIVES NOW
EQ 0.5GM BASE;2GM/VIAL	AVYCAZ	ALLERGAN	N206494	Feb. 25, 2015	RX	POWDER	INTRAVENOUS	Dec. 20, 2025	NEW PATIENT POPULATION

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Peptidoglycan synthase FtsI	Enzyme		FTSI_ECOLI	INHIBITOR	IC50	6.26		WOMBAT-PK	CHEMBL
Penicillin-binding protein 1A	Enzyme		PBPA_ECOLI	INHIBITOR	IC50	6.53		WOMBAT-PK	CHEMBL
Penicillin-binding protein 1B	Enzyme		PBPB_ECOLI	INHIBITOR	IC50	4.96		WOMBAT-PK	CHEMBL

External reference:

ID	Source
4017550	VUID
N0000145931	NUI
D00921	KEGG_DRUG
73547-61-2	SECONDARY_CAS_RN
203418	RXNORM
C0007559	UMLSCUI
CHEBI:3508	CHEBI
CHEMBL44354	ChEMBL_ID
CHEMBL1200768	ChEMBL_ID
D002442	MESH_DESCRIPTOR_UI
DB00438	DRUGBANK_ID
10762	IUPHAR_LIGAND_ID
9M416Z9QNR	UNII
5481173	PUBCHEM_CID
1047	MMSL
173313	MMSL
2299	MMSL
2303	MMSL
30973	MMSL
4383	MMSL
4384	MMSL
d00009	MMSL
002735	NDDF
006723	NDDF
006724	NDDF
36893000	SNOMEDCT_US
387200005	SNOMEDCT_US
725671004	SNOMEDCT_US
4017550	VANDF
78439-06-2	SECONDARY_CAS_RN

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Ceftazidime and Dextrose	HUMAN PRESCRIPTION DRUG LABEL	1	0264-3143	INJECTION, SOLUTION	1 g	INTRAVENOUS	NDA	29 sections
Ceftazidime and Dextrose	HUMAN PRESCRIPTION DRUG LABEL	1	0264-3145	INJECTION, SOLUTION	2 g	INTRAVENOUS	NDA	29 sections
TAZICEF	HUMAN PRESCRIPTION DRUG LABEL	1	0409-5082	INJECTION, POWDER, FOR SOLUTION	1 g	INTRAMUSCULAR	ANDA	24 sections
TAZICEF	HUMAN PRESCRIPTION DRUG LABEL	1	0409-5082	INJECTION, POWDER, FOR SOLUTION	1 g	INTRAMUSCULAR	ANDA	24 sections
TAZICEF	HUMAN PRESCRIPTION DRUG LABEL	1	0409-5082	INJECTION, POWDER, FOR SOLUTION	1 g	INTRAMUSCULAR	ANDA	24 sections
TAZICEF	HUMAN PRESCRIPTION DRUG LABEL	1	0409-5084	INJECTION, POWDER, FOR SOLUTION	2 g	INTRAVENOUS	ANDA	24 sections
TAZICEF	HUMAN PRESCRIPTION DRUG LABEL	1	0409-5084	INJECTION, POWDER, FOR SOLUTION	2 g	INTRAVENOUS	ANDA	24 sections
TAZICEF	HUMAN PRESCRIPTION DRUG LABEL	1	0409-5084	INJECTION, POWDER, FOR SOLUTION	2 g	INTRAVENOUS	ANDA	24 sections
TAZICEF	HUMAN PRESCRIPTION DRUG LABEL	1	0409-5086	INJECTION, POWDER, FOR SOLUTION	6 g	INTRAVENOUS	ANDA	24 sections
TAZICEF	HUMAN PRESCRIPTION DRUG LABEL	1	0409-5086	INJECTION, POWDER, FOR SOLUTION	6 g	INTRAVENOUS	ANDA	24 sections
TAZICEF	HUMAN PRESCRIPTION DRUG LABEL	1	0409-5086	INJECTION, POWDER, FOR SOLUTION	6 g	INTRAVENOUS	ANDA	24 sections
TAZICEF	HUMAN PRESCRIPTION DRUG LABEL	1	0409-5092	INJECTION, POWDER, FOR SOLUTION	1 g	INTRAVENOUS	ANDA	25 sections
TAZICEF	HUMAN PRESCRIPTION DRUG LABEL	1	0409-5093	INJECTION, POWDER, FOR SOLUTION	2 g	INTRAVENOUS	ANDA	25 sections
AVYCAZ	HUMAN PRESCRIPTION DRUG LABEL	2	0456-2700	POWDER, FOR SOLUTION	2 g	INTRAVENOUS	NDA	30 sections
AVYCAZ	HUMAN PRESCRIPTION DRUG LABEL	2	0456-2700	POWDER, FOR SOLUTION	2 g	INTRAVENOUS	NDA	30 sections
Ceftazidime	HUMAN PRESCRIPTION DRUG LABEL	1	25021-127	INJECTION, POWDER, FOR SOLUTION	1 g	INTRAVENOUS	ANDA	26 sections
Ceftazidime	HUMAN PRESCRIPTION DRUG LABEL	1	25021-127	INJECTION, POWDER, FOR SOLUTION	1 g	INTRAVENOUS	ANDA	26 sections
Ceftazidime	HUMAN PRESCRIPTION DRUG LABEL	1	25021-128	INJECTION, POWDER, FOR SOLUTION	2 g	INTRAVENOUS	ANDA	26 sections
Ceftazidime	HUMAN PRESCRIPTION DRUG LABEL	1	25021-128	INJECTION, POWDER, FOR SOLUTION	2 g	INTRAVENOUS	ANDA	26 sections
Ceftazidime	HUMAN PRESCRIPTION DRUG LABEL	1	25021-129	INJECTION, POWDER, FOR SOLUTION	6 g	INTRAVENOUS	ANDA	26 sections
Ceftazidime	HUMAN PRESCRIPTION DRUG LABEL	1	25021-129	INJECTION, POWDER, FOR SOLUTION	6 g	INTRAVENOUS	ANDA	26 sections
Ceftazidime	HUMAN PRESCRIPTION DRUG LABEL	1	44567-235	INJECTION, POWDER, FOR SOLUTION	1 g	INTRAVENOUS	ANDA	24 sections
Ceftazidime	HUMAN PRESCRIPTION DRUG LABEL	1	44567-236	INJECTION, POWDER, FOR SOLUTION	2 g	INTRAVENOUS	ANDA	24 sections
Ceftazidime	HUMAN PRESCRIPTION DRUG LABEL	1	44567-237	INJECTION, POWDER, FOR SOLUTION	6 g	INTRAVENOUS	ANDA	25 sections
FORTAZ	HUMAN PRESCRIPTION DRUG LABEL	1	52565-105	INJECTION, POWDER, FOR SOLUTION	100 mg	INTRAMUSCULAR	NDA	24 sections
FORTAZ	HUMAN PRESCRIPTION DRUG LABEL	1	52565-106	INJECTION, POWDER, FOR SOLUTION	100 mg	INTRAMUSCULAR	NDA	24 sections
FORTAZ	HUMAN PRESCRIPTION DRUG LABEL	1	52565-107	INJECTION, POWDER, FOR SOLUTION	170 mg	INTRAMUSCULAR	NDA	24 sections
FORTAZ	HUMAN PRESCRIPTION DRUG LABEL	1	52565-109	INJECTION, POWDER, FOR SOLUTION	200 mg	INTRAMUSCULAR	NDA	25 sections